Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 15, 2022, Galera Therapeutics, Inc. (the "Company") held its Annual
Meeting of Stockholders. A total of 17,223,141 shares of common stock were
present online or represented by proxy at the meeting, representing
approximately 64.21 percent of the Company's outstanding common stock as of the
April 22, 2022 record date. The following are the voting results for the
proposals considered and voted upon at the meeting, all of which were described
in the Company's definitive proxy statement filed with the Securities and
Exchange Commission on April 28, 2022.
Item 1 - Election of two Class III Directors to serve until the 2025 Annual
Meeting of Stockholders, and until their respective successors have been duly
elected and qualified.
NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes
Emmett Cunningham, M.D., Ph.D. 10,555,231 940,717 5,727,193
J. Mel Sorensen, M.D.
10,744,609 751,339 5,727,193
Item 2 - Ratification of the appointment of KPMG LLP as the Company's
independent registered public accounting firm for the year ending December 31,
2022.
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes
17,167,149 46,053 9,939 0
Based on the foregoing votes, Emmett Cunningham, M.D., Ph.D. and J. Mel
Sorensen, M.D. were elected as Class III Directors and Item 2 was approved.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
